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TRIAL INFORMATION
• ClinicalTrials.gov Identifier: NCT02000375
• Sponsor(s): None
• Principal Investigator: Elisabetta Pietri
• IRB Approved: Yes
LESSONS LEARNED
• The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited.
• This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC
cells, in combination with an aromatase inhibitor (to block DHEA conversion into estrogens), in a two-stage phase II study in
patients with AR-positive/estrogen receptor-positive/human epidermal growth receptor 2-negative metastatic BC.
• Although well tolerated, only 1 of 12 patients obtained a prolonged clinical benefit, and the study was closed after its
first stage for poor activity.
ABSTRACT
Background. Androgen receptors (AR) are expressed in
most breast cancers, and AR-agonists have some activity in
these neoplasms. We investigated the safety and activity of
the androgen precursor dehydroepiandrosterone (DHEA) in
combination with an aromatase inhibitor (AI) in patients
with AR-positive metastatic breast cancer (MBC).
Methods. A two-stage phase II study was conducted in two
patient cohorts, one with estrogen receptor (ER)-positive
(resistant to AIs) and the other with triple-negative MBC.
DHEA 100 mg/day was administered orally. The combina-
tion with an AI aimed to prevent the conversion of DHEA
into estrogens. The main endpoint was the clinical benefit
rate. The triple-negative cohort was closed early.
Results. Twelve patients with ER-positive MBC were
enrolled. DHEA-related adverse events, reported in four
patients, included grade 2 fatigue, erythema, and transami-
nitis, and grade 1 drowsiness and musculoskeletal
pain. Clinical benefit was observed in one patient with
ER-positive disease whose tumor had AR gene amplifica-
tion. There was wide inter- and intra-patient variation in
serum levels of DHEA and its metabolites.
Conclusion. DHEA showed excellent safety but poor activity
in MBC. Although dose and patient selection could be
improved, high serum level variability may hamper further
DHEA development in this setting. The Oncologist
2018;23:1–10
DISCUSSION
Androgen receptors are commonly expressed in BC, but
androgens have variable effects in different BC subtypes,
and both AR-agonists and AR-antagonists have been stud-
ied as anticancer agents in these tumors.
This multicenter, single-arm, two-stage phase II study
evaluated the safety and activity of the androgen precursor
DHEA, 100 mg/day orally continuously, in combination with
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an AI to prevent its transformation into estrogens, in two
cohorts of patients with AR-positive metastatic BC: one
with ER-positive/human epidermal growth factor receptor
2 (HER2)-negative and one with triple-negative disease.
Patients were postmenopausal and, when ER-positive,
had documented resistance to both nonsteroidal and ste-
roidal AIs. The primary endpoints were safety and activity
(clinical benefit rate: proportion of patients with stable dis-
ease or objective response after 16 weeks).
From November 2013 to July 2015, 12 patients were
enrolled in the ER-positive and 6 in the triple-negative
cohort; the last closed early, due to emerging preclinical
evidence of tumor stimulation by androgens.
In the ER-positive cohort, the median age was 74 years,
Eastern Cooperative Oncology Group (ECOG) performance sta-
tus 0–2; nine patients had visceral metastases, five were pre-
treated with 1–2 lines of chemotherapy and all with 1–4 lines
of endocrine therapy for advanced disease. The median dura-
tion of treatment was 71 days (range 55–697). Seven patients
showed progressive disease (PD) at 8 weeks, four had stable
disease (SD) at 8 weeks and PD at 16 weeks, and one had SD
lasting >16 weeks (692 days). Median time to progression
(TTP) was 63 days (95% confidence interval [CI] 57–126) and
median overall survival (OS) 559 days (95% CI 134–not
reached; Fig. 1). The study closed after the first stage for poor
activity. All patients in the triple-negative cohort had PD.
Toxicities deemed to be related to DHEA were (worst
grades) G2 fatigue, facial erythema, and increase in trans-
aminases (the last required temporary treatment interrup-
tion) and G1 sleepiness and joint/muscular pain. Other
toxicities, attributable to AIs or the underlying disease,
included four serious adverse events: uncontrolled pain,
trauma, seizure, and constipation, and all but the last were
considered not treatment related.
There was wide intra- and inter-patient variability in
DHEA serum levels.
The patient who experienced prolonged SD was the
only one showing AR gene amplification.
The combination DHEA-AI was well tolerated but poorly
active in ER-positive metastatic BC. Although dose and
patient selection could be further studied, variability in
serum levels and in tumor intracrinology (the intracellular
formation of sex steroids from DHEA) may hamper further
DHEA development in BC.
TRIAL INFORMATION
Disease Breast cancer
Stage of Disease/Treatment Metastatic/advanced
Prior Therapy More than two prior regimens
Type of Study – 1 Phase II
Type of Study – 2 Single arm
Primary Endpoint Clinical benefit rate (proportion of patients with stable disease
or objective response after 16 weeks of therapy)
Primary Endpoint Safety
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Figure 1. (A) Time to progression and (B) overall survival of the estrogen receptor-positive cohort.
Abbreviations: OS, overall survival; TTP, time to progression.
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Secondary Endpoint Toxicity
Secondary Endpoint Overall response rate
Secondary Endpoint Time to progression
Secondary Endpoint Overall survival
Secondary Endpoint Correlative endpoint
Additional Details of Endpoints or Study Design
Study design: Simon two-stage design with 10% alpha and beta errors. Assuming an acceptable minimum clinical benefit of
10% and a desirable clinical benefit of 30%, 12 patients were required per cohort in the first stage, with the intent to continue
recruitment up to a total of 35 patients per cohort if the number of patients achieving clinical benefit was ≥2 at the first
stage, and considering the combination active if the total number of patients achieving clinical benefit was ≥6 in the entire
cohort. Descriptive statistics are reported as frequencies and percentages for categorical variables and as median and range
for continuous variables. Boxplots are used to represent serum levels of DHEA and glucuronidated metabolites at different
time points, and the Friedman nonparametric repeated measure analysis of variance was used to test differences in their
distribution over time. TTP and OS curves were estimated using the Kaplan-Meier method.
Correlative endpoints: (a) On formalin fixed, paraffin-embedded tumor samples, we assessed AR expression (AR Cell Marque
antibody, clone SP107; Ventana Medical Systems, Oro Valley, AZ) and phosphorylation (Novus Biologicals pSer
650 NBP1-60769 and pSer 210- 213 NB 100-56603 antibodies; Novus Biologicals, Littleton, CO) by immunohistochemistry
and AR gene copy number by fluorescence in situ hybridization using Vysis LSI Androgen Receptor Gene (Xq12)
SpectrumOrange Probe kit (Abbott Molecular, Des Plaines, IL); (b) measurement of serum levels of DHEA and of its
glucuronidated metabolites androstane-3alpha,17beta-diol-3-glucuronide (3-diol-3G), androstane-3alpha,17beta-diol-
17glucuronide (3-diol-17G), and androsterone glucuronide (ADT-G) [44].
Investigator’s Analysis Level of activity did not meet planned endpoint
DRUG INFORMATION
Drug 1
Generic/Working Name Dehydroepiandrosterone
Trade Name Company Name
Drug Type Androgen precursor
Drug Class Androgen receptor
Dose 100 mg flat dose
Route p.o.
Schedule of Administration 100 mg/day continuously
Drug 2
Generic/Working Name Anastrozole or exemestane or letrozole
Trade Name Company Name
Drug Type Aromatase inhibitor
Drug Class Estrogen receptor
Dose 1, 25, 2.5 (respectively) mg flat dose
Route p.o.
Schedule of Administration 1 tablet/day continuously
PATIENT CHARACTERISTICS
Number of Patients, Male 0
Number of Patients, Female 18
Stage Stage IV breast cancer
Age Median (range): 74 (50–90)
Number of Prior Systemic Therapies Median (range): 2 (1–4)
Performance Status: ECOG 0 — 14
1 — 3
2 — 1
3 —
Unknown —
Cancer Types or Histologic Subtypes Estrogen receptor-positive, HER2-negative breast cancer, 12
Triple-negative breast cancer, 6
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PRIMARY ASSESSMENT METHOD
Title Estrogen receptor-positive, HER2-negative cohort
Number of Patients Screened 13
Number of Patients Enrolled 12
Number of Patients Evaluable for Toxicity 12
Number of Patients Evaluated for Efficacy 12
Evaluation Method RECIST 1.1
Response Assessment CR n = 0 (0%)
Response Assessment PR n = 0 (0%)
Response Assessment SD n = 5 (42%)
Response Assessment PD n = 7 (58%)
(Median) Duration Assessments TTP 63 days, CI: 57–126
(Median) Duration Assessments OS 559 days, CI: 134–not reached [NR]
(Median) Duration Assessments Duration of Treatment 71 days
Outcome Notes
Clinical benefit rate (CR or PR or SD at week 16): one patient (8%). Enrollment in the triple-negative cohort was closed in
advance because of both slow recruitment and preclinical data suggesting that AR may drive tumor progression in some
subtypes of triple-negative breast cancer.
Title Triple-negative cohort
Number of Patients Screened 7
Number of Patients Enrolled 6
Number of Patients Evaluable for Toxicity 6
Number of Patients Evaluated for Efficacy 6
Evaluation Method RECIST 1.1
Response Assessment CR n = 0 (0%)
Response Assessment PR n = 0 (0%)
Response Assessment SD n = 1 (17%)
Response Assessment PD n = 5 (83%)
(Median) Duration Assessments TTP 55 days, CI: 13–NR
(Median) Duration Assessments OS 339 days, CI: 63–NR
(Median) Duration Assessments Duration of Treatment 68 days
Outcome Notes
Enrollment in the triple-negative cohort was closed in advance because of both slow recruitment and preclinical data
suggesting that AR may drive tumor progression in some subtypes of triple-negative breast cancer.
ADVERSE EVENTS
All Cycles
Name NC/NA 1 2 3 4 5 All grades
Gastrointestinal pain 94% 6% 0% 0% 0% 0% 6%
Fatigue 77% 17% 6% 0% 0% 0% 23%
Anorexia 89% 11% 0% 0% 0% 0% 11%
Dysphagia 94% 6% 0% 0% 0% 0% 6%
Dyspepsia 88% 6% 6% 0% 0% 0% 12%
Nausea 83% 17% 0% 0% 0% 0% 17%
Vomiting 89% 11% 0% 0% 0% 0% 11%
Constipation 94% 6% 0% 0% 0% 0% 6%
Diarrhea 89% 11% 0% 0% 0% 0% 11%
Enterocolitis infectious 94% 0% 6% 0% 0% 0% 6%
Dyspnea 89% 11% 0% 0% 0% 0% 11%
Cough 88% 6% 6% 0% 0% 0% 12%
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Fever 94% 6% 0% 0% 0% 0% 6%
Hot flashes 94% 0% 6% 0% 0% 0% 6%
Agitation 94% 6% 0% 0% 0% 0% 6%
Insomnia 89% 11% 0% 0% 0% 0% 11%
Dizziness 94% 6% 0% 0% 0% 0% 6%
Hypertension 94% 6% 0% 0% 0% 0% 6%
Rash maculo-papular 94% 0% 6% 0% 0% 0% 6%
Skin and subcutaneous tissue disorders - psoriasiform lesions 94% 6% 0% 0% 0% 0% 6%
Localized edema 94% 6% 0% 0% 0% 0% 6%
Aspartate aminotransferase increased 94% 6% 0% 0% 0% 0% 6%
Arthralgia 60% 17% 17% 6% 0% 0% 40%
Cholesterol high 94% 0% 6% 0% 0% 0% 6%
Number of patients experiencing a given toxicity, among 18 patients assessable for toxicity (each patient was registered under the maximum
grade experienced for each kind of toxicity).
Abbreviation: NC/NA, no change from baseline/no adverse event.
SERIOUS ADVERSE EVENTS
Name Grade Attribution
Uncontrolled pain 2 Unrelated
Cranial trauma 2 Unrelated
Seizures 2 Unrelated
Constipation and abdominal pain 2 Unlikely
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Investigator’s Assessment Level of activity did not meet planned endpoint
Androgen receptors (AR) are expressed in 60%–90% of
breast cancers (BC), mainly in estrogen receptor (ER)-
positive tumors [1, 2]. Androgens have variable effects in
different BC models [3–5]: often antiproliferative [6–13],
mainly in ER-positive tumors; sometimes pro-proliferative
[14–18], mainly in triple-negative and human epidermal
growth factor receptor 2 (HER2)-positive/ER-negative
tumors. Both AR-agonists [19–22] and AR-antagonists are
being studied as antitumor agents in BC [23–27]. Dehydro-
epiandrosterone (DHEA) is a steroid produced mainly by the
adrenal cortex and transformed into sex hormones (andro-
gens and estrogens) within peripheral target tissues [28–33].
The action of sex steroids is confined within the cells in
which they are synthesized (a process called “intracrinol-
ogy”), with little or no release into the extracellular spaces
or the general circulation. This process also occurs within BC
cells, and there is preclinical evidence of antitumor activity
of DHEA in BC [34–40]. The administration of an aromatase
inhibitor (AI) prevents the conversion of DHEA into estro-
gens and favors its conversion into androgens.
To investigate the role of androgens in BC, avoiding the
virilizing effects of available androgenic agents, we con-
ducted a two-stage, phase II, prospective clinical study to
evaluate the safety and activity of DHEA 100 mg/day in
combination with an AI (anastrozole 1 mg/day, letrozole
2.5 mg/day, or exemestane 25 mg/day) in two cohorts of
patients with AR-positive metastatic breast cancer: one
with ER-positive/HER2-negative (ER-positive cohort) and
one with triple-negative (TN cohort) disease.
The DHEA dosage was chosen based on the reported
saturation of the enzymatic systems that transform DHEA
into sex steroids, occurring at serum levels of about
7 ng/mL [41, 42], and to the reported serum DHEA levels
of about 7 ng/mL achieved after oral administration of
DHEA 100 mg daily for 6 months [43]. DHEA was produced
by the Oncology Pharmacy Laboratory of our institute,
whereas AIs were purchased commercially.
Serum levels of DHEA and its glucuronidated metabo-
lites were measured by liquid chromatography-tandem
mass spectrometry [44]. The expression of AR and of its
main phosphorylated forms (AR 650 and AR 210-213) was
assessed by immunohistochemistry and AR gene amplifica-
tion by fluorescence in situ hybridization.
Patients characteristics are reported in the designated
Table. All patients in the ER-positive cohort had developed
resistance to both nonsteroidal and steroidal AIs. Seven
patients had received an AI as their last line of treatment
before entering the trial and, after progressing on the AI,
had continued the same AI but with the addition of DHEA.
Conversely, five patients received DHEA in combination
with an AI to which they had developed resistance in the
past, but which was not the last line of therapy they
received before entering this trial.
Toxicity is reported in the "adverse events" table. The
four serious adverse events reported were not attributed to
DHEA. Two patients died within 30 days of the end of ther-
apy, one after 8 days and one after 21 days, all due to tumor
progression. No virilizing effects were registered.
© AlphaMed Press 2018www.TheOncologist.com
Pietri, Massa, Bravaccini et al. 5
Published Ahead of Print on December 27, 2018 as 10.1634/theoncologist.2018-0243. 
 by guest on January 4, 2019
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
Only one patient had clinical benefit, with stable dis-
ease (SD) for almost 99 weeks. She had previously received
letrozole for 4 years for a regional relapse and then tamox-
ifen for 8 months upon progression. Following further pro-
gression, she was enrolled in the trial and received
letrozole + DHEA.
The three patients whose tumors showed lower AR
expression levels (<50% of positive cells and H-score < 100)
had disease progression (PD) after 8 weeks, whereas five
of the seven patients with higher AR expression showed
SD at this time. AR phosphorylation and AR gene copy
number were available for 10 patients (Table 2). Remark-
ably, the patient with clinical benefit was the only one
whose tumor harbored an AR gene amplification, with AR
gene clusters observed in 20% of tumor cells. All tumor
samples showed AR phosphorylation at serine 650 (p650)
in variable amounts and at different locations (cytoplasm
or nucleus). The two patients with lower p650 H-scores
(<100) had PD at 8 weeks, whereas of the eight patients
with intermediate/high H-scores, five had SD and three
had disease progression at 8 weeks. The patient who expe-
rienced prolonged SD had a nuclear expression of p650,
whereas in most cases p650 was found in the cytoplasm.
AR phosphorylation at serine 210-213 was present, mainly
in the nucleus, in only three patients, one of whom was
the patient with prolonged SD.
Serum levels of DHEA and its glucuronidated metabolites
androstane-3alpha,17beta-diol-3-glucuronide (3α-diol-3G),
androstane-3alpha,17beta-diol-17glucuronide (3α-diol-17G),
and androsterone glucuronide (ADT-G) were measured at
baseline, at 8 weeks, and at the end of treatment in
10 patients. DHEA was assessable at all three time-points
in four patients, 3α-diol-3G in two patients, 3α-diol-17G in
seven patients, and ADT-G in eight patients. There was wide
intra- and interpatient variation in DHEA serum levels
(Fig. 2), but no significant changes over time were observed,
probably because of the small number of patients with all
measurements (p = .333). Only one patient had DHEA values
constantly above the target threshold of 7 ng/mL and pro-
gressed after 8 weeks. The patient with prolonged disease
stabilization had a median DHEA serum level of 4.01 ng/mL.
Among the glucuronidated metabolites (Fig. 3), median
serum levels of 17α-diol-17G and ADT-G showed significant
changes over time (p = .020 and p = .007, respectively, Fried-
man test). No clear pattern of metabolite levels emerged in
relation to response to treatment at 8 weeks.
The poor activity of DHEA in our study may partly be
due to heavy pretreatment, which may have compromised
hormone sensitivity. Variability in adrenal function [45], in
DHEA disposition after oral administration especially in
elderly patients [46–59], and in BC cells intracrinology may
further be involved [60].
The AR gene amplification present in the only patient
who showed a prolonged clinical benefit is intriguing,
prompting to hypothesize the potential value of AR gene
amplification as a predictive biomarker of response to
androgenic treatments in breast cancer. However, the small
number of patients involved in the study and the low rate
of clinical benefit prevents any definitive conclusions from
being drawn. Similarly, the role of phosphorylated AR
remains to be ascertained.
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Figure 2. Individual serum concentrations of dehydroepiandrosterone (DHEA) and metabolites in 10 patients from the estrogen
receptor-positive cohort. The following are reported for each patient: Left panels: serum concentrations of DHEA, androstane-
3alpha,17beta-diol-3-glucuronide (3α-diol-3G), and androstane-3alpha,17beta-diol-17glucuronide (3α-diol-17G) at different time
points during treatment. Right panels: serum concentrations of androsterone glucuronide (ADT-G) at different time points during
treatment. Solid line: DHEA levels; dotted line: 3α-diol-3G levels; dashed line: 3α-diol-17G levels; dash-dotted line: ADT-G levels.
Abbreviations: Baseline, before starting treatment; C1D14, cycle 1 day 14; C2D1, cycle 2 day 1; EOT, end of treatment.
FIGURES AND TABLES
© AlphaMed Press 2018
DHEA in AR-Positive Metastatic Breast Cancer8
Published Ahead of Print on December 27, 2018 as 10.1634/theoncologist.2018-0243. 
 by guest on January 4, 2019
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
Table 1. Patient and tumor characteristics
Variable Cohort 1 (n = 12), n (%) Cohort 2 (n = 6), n (%)
Median age, years (range) 74 (58–90) 76 (50–86)
Performance status (ECOG)
0 9 (75) 5 (83)
1 2 (17) 1 (17)
2 1 (8) —
Hormone receptorsa
Androgen-positive 12 6
Estrogen-positive 12 —
Estrogen-negative 6
Progesterone-positive 9 (75) —
Progesterone-negative 3 (25) 6
Negative HER2 statusa 12 6
Number of metastatic sites
1 2 (16.67) 1 (17)
2 2 (16.67) 2 (33)
3 6 (50.00) 2 (33)
4 2 (16.67) 1 (17)
Sites of metastases
Soft tissues (only) 2 (17) 0
Bone ( soft tissue) 1 (8) 1 (17)
Viscera ( other) 9 (75) 5 (83)
Previous lines of hormone therapy for MBC
1 1 (8) —
2 6 (50) —
3 3 (25) —
4 2 (17) —
Previous lines of chemotherapy for MBC
0 7 (58) 1 (17)
1 3 (25) 1 (17)
2 2 (17) 2 (33)
3 — 2 (33)
Chosen aromatase inhibitor
Exemestane 6 (50) 4 (67)
Anastrozole 4 (33) 2 (33)
Letrozole 2 (17) —
Last line of therapy before enrollment into
this clinical trial
Same AI, continued within this study 7 (58)
Other treatment 5 (42)
aBased on the most recent tumor biopsy performed (Cohort 1: six primary tumors and six metastases; Cohort 2: three primary tumors and
three metastases).
Abbreviations: —, no data; AI, aromatase inhibitor; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth receptor 2;
MBC, metastatic breast cancer.
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Figure 3. Boxplots of serum concentrations of DHEA and metabolites. Box and whisker plots, showing the median, interquartile
range, and the highest and lowest values for each analyte at three time points (baseline, cycle 2 day 1, and end of treatment).
Abbreviations: C2, cycle 2 day 1; DHEA, dehydroepiandrosterone; EOT, end of treatment.
Table 2. Androgen receptor expression, phosphorylation, and gene amplification
Patient Site
AR (nuclear) AR
FISH
AR p650 AR p210-213 Response
at 8 weeks% Int H % N C Int H % N C Int H
1 M (chest wall skin) 70 3 210 + 45 + − 2-3 135 10 + − 1 10 SD
2 P 90 3 270 − 90 − + 3 270 0 PD
3 P 90 3 270 − 80 + + 3 240 35 + + 1 35 SD
4 P 30 2 60 − 95 − + 3 285 0 PD
5 P 90 3 270 − 50 − + 2-3 150 30 + − 1 30 PD
6 M (chest wall skin) 95 3 285 − 100 − + 3 300 0 SD
7 P (relapse) 85 3 255 − 90 − + 3 270 0 SD
8 M (mediastinum) 80 3 240 − 90 − + 3 270 0 SD
9 P 25 2 50 − 70 + − 1 70 0 PD
10 P 30 3 90 − 30 + + 2 60 0 PD
Abbreviations: %, percentage of stained cells; AR, androgen receptor; AR FISH, AR gene amplification by fluorescence in situ hybridization; C,
cytoplasm; H, H-score (= % * Int); Int, staining intensity; M, metastasis; N, nuclear; P, primary tumor; p650, phosphorylation at serine 650;
p210-213, phosphorylation at serine 210-213; PD, progressive disease; SD, stable disease.
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